HomeStocksNATCOPHARM

N

Natco Pharma

NATCOPHARM Share PriceHealthcare

₹ 834.60

5.95 (0.72%)profit
as on 07 Sep 2026 at 11:13 AM
views911
portfolio2.8K
analyst37.5% Buy
Overview
Pros & Cons
News
History
Fundamentals
Investment Returns
Technicals
Financials
Balance Sheet
Cash Flow
Corporate Actions
Peers

Natco Pharma Share Price Today

Today Natco Pharma opened at 829.00 while its previous close was at 828.65. In todays trading session NATCOPHARM reached a high of 841.50 and low of 828.00. The average traded price for today is 835.19. The 50 DMA stands at 915.35 and 200 DMA is at 945.55. Looking at intraday trend, the stock is moving sideways.

50 DMA: 915.35200 DMA: 945.55
chartsarrowTradingViewarrow

Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.

Use Chart

NATCOPHARM Stock Performance

Markets Today

High

841.50

Low

828.00

Open at

829.00

Prev Close

828.65

Volumes

1,14,422

Avg Price

835.19

Lower Circuit

662.95

Upper Circuit

994.35

Last Traded Details

Quantity

2

Time

11:13:46

Price Movement

828.00841.50
0.80%Loss
down side
up side
0.82%Profit

Historical Performance

3 M High

997.30

3 M Low

826.50

1 Yr High

1,226.80

1 Yr Low

789.00

3 Yr High

1,639.00

3 Yr Low

724.20

5 Yr High

1,639.00

5 Yr Low

502.00

1-Year Performance

789.001,226.80
5.78%Loss
down side
up side
31.97%Profit
View In-Deptharrow

NATCOPHARM Pros and Cons

byfuzz AI

API revenue grows from ₹526 Cr in Q1 FY26 to ₹667 Cr in Q1 FY27, showing steady segment expansion.

Domestic formulations revenue rises from ₹1,070 Cr in Q1 FY26 to ₹1,364 Cr in Q1 FY27, confirming strong local demand.

Share of profit from associates jumps from ₹11 Cr in Q3 FY26 to ₹843 Cr in Q1 FY27, boosting consolidated earnings.

Total expenses fall from ₹7,579 Cr in Q1 FY26 to ₹5,487 Cr in Q1 FY27, reflecting disciplined cost control.

Crop health sciences revenue recovers from ₹285 Cr in Q3 FY26 to ₹408 Cr in Q1 FY27, indicating seasonal strength.

Consolidated revenue drops from ₹13,906 Cr in Q1 FY26 to ₹7,944 Cr in Q1 FY27, highlighting top-line contraction.

International formulations revenue falls from ₹11,265 Cr in Q1 FY26 to ₹4,771 Cr in Q1 FY27, pointing to export headwinds.

Profit after tax declines from ₹4,803 Cr in Q1 FY26 to ₹1,222 Cr in Q1 FY27, showing sustained earnings pressure.

Finance cost rises from ₹32 Cr in Q1 FY26 to ₹130 Cr in Q1 FY27, increasing debt servicing burden.

EBITDA slips from ₹6,327 Cr in Q1 FY26 to ₹2,457 Cr in Q1 FY27, reflecting margin compression.

fuzz Insights
Positive

API sales are climbing. Company costs are actually falling.

Neutral

Profits look stable. But that's the savings account talking, not the factory.

Neutral

Asset write-offs are down. Operating cash generation isn't up.

Neutral

Local sales are booming. The company top line is stuck.

Negative

Export sales collapsed. Overall profitability followed suit.

Negative

Borrowing costs are spiking. Net profits are shrinking.

NATCOPHARM Analyst Rating

Buy

Analysts have suggested that investors can Buy this Stock

- By Refinitiv from 8 analysts

Buy

37.5%

Hold

25%

Sell

37.5%

Get forecast for Price, ROA & ROE based on analyst ratings.

Get Forecast

NATCOPHARM Latest News

View Allarrow

NATCOPHARM Share Price History

View In-Deptharrow

NATCOPHARM Fundamentals

Company Valuation

Market Cap (₹ Cr.)

14,949

PE Ratio

13.00

PB Ratio

1.61

Dividend Yield

0.18%

ROE

24.74%

ROCE

30.12%

Book Value (₹)

514.83

Face Value (₹)

2.00

Analyse NATCOPHARM with 12+ custom fundamentals and financial ratios.

Analyse Now

Share Holding Pattern

Held ByJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
49.56%49.48%49.48%49.42%49.42%
Domestic Institutional Investors (DII)
5.82%5.87%5.39%5.46%5.62%
Foreign Institutional Investors (FII)
15.51%14.09%15.16%17.37%16.99%
Public Investors
25.22%25.84%25.38%23.34%23.41%
Government
0.00%0.00%0.00%0.00%0.00%

Promoters

Domestic Institutional Investors (DII)

Foreign Institutional Investors (FII)

Public Investors

Government

View In-Deptharrow

Natco Pharma Return Calculator

You have invested
Investment Period

Current value of ₹1,00,000 invested 5 years ago, as on today

₹ 0

Loss

₹ 1,00,000 (16.08%)

Invest Now

Note: Past profits do not guarantee future returns.

NATCOPHARM Investment Returns

1 Week

1 Month

3 Months

6 Months

9 Months

View In-Deptharrow

Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.

Start SIP

NATCOPHARM Technicals

Moving Averages

PeriodSimpleSignal
5-SMA840.18Bearish
10-SMA852.60Bearish
20-SMA877.43Bearish
50-SMA915.35Bearish
100-SMA976.87Bearish
200-SMA945.55Bearish

Technical Indicators

IndicatorValueAction
RSI(14)29.17Neutral
ATR(14)22.66Less Volatile
STOCH(9,6)11.29Oversold
STOCH RSI(14)8.98Oversold
MACD(12,26)-3.42Bearish
ADX(14)14.45Weak Trend

Summary of Technical Indicators for NATCOPHARM

View In-Deptharrow

Margin on NATCOPHARM

Order TypeMargin to PayLeverageQuantityTrade ValueMargin AmountActions

*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions. Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).

NATCOPHARM Financials Summary

View By:
Revenue
EBITDA
Net Profit
EPS
Revenue

In Crores

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,3911,463705817794

NATCOPHARM Financials

View by

Income Statement

In Cr

Quarterly StatementJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,3911,463705817794
Expenses758784489612549
633679217205246
Operating Profit571579159128187
Operating Profit Margin %43%42%25%17%25%
Other Income62100587859
Interest313101113
Depreciation5852465047
572614161144186
Tax %16%16%6%-87%-11%
Net Profit480518151269207
EPS272981512

Balance Sheet

In Cr

Yearly Balance SheetMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
5,1095,6576,9068,63111,074
Fixed Assets2,3122,4272,4912,6983,033
Current Assets2,4973,0004,0245,2705,052
Capital Work in Progress13064137225294
Investments308392539474909
Other Assets2,3602,7743,7395,2340
5,1095,6576,9068,63111,074
Current Liabilities7106839739441,681
Non Current Liabilities1351018075172
4,2644,8745,8537,6129,221
Reserve & Surplus4,2274,8375,8177,5719,185
Share Capital3737363636
Minority Interest00050

Cash Flow

In Cr

Yearly Cash FlowMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Activities299478491,2121,697
Investing Activities-1074-465-1,026-1,437
Financing Activities-18635-363-247-211
Net Cash Flow68521-6250
View In-Deptharrow

Corporate Actions

DateCorporate ActionInformation
20th Aug 2026, Thursday
DIVIDENDDividend
Interim Dividend of ₹1.5/share
14th Aug 2026, Friday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q1 FY 26-27 Results
info
29th May 2026, Friday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q4 FY 26-27 Results
info
18th Feb 2026, Wednesday
DIVIDENDDividend
Interim 3 Dividend of ₹1.5/share
12th Feb 2026, Thursday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q3 FY 25-26 Results
info

The above dates are ex-dates.

View Allarrow

Check NATCOPHARM latest Company Filings, Investor Presentation & Conference Call details.

Read Now

NATCOPHARM Revenue Growth

All values are in Crores

Revenue

Profit

Loss

Financial YearRevenueRevenue GrowthNet ProfitProfit Growth
FY 2024-253,595
20.2% profit
1,096
41.62% profit
FY 2023-244,416
50.77% profit
1,850
105.09% profit
FY 2022-233,674
30.83% profit
1,307
358.02% profit

Top Mutual Funds Invested in NATCOPHARM

NATCOPHARM Popular Brands

NATCOPHARM Similar Stocks

Stock NamePrice
Sun Pharmaceutical

S

Sun Pharmaceutical

1,900.00+0.05%profit
Divis Laboratories

D

Divis Laboratories

9,269.50+1.86%profit
Torrent Pharmaceuticals

T

Torrent Pharmaceuticals

4,897.50+0.83%profit
Zydus Life Science

Z

Zydus Life Science

1,135.60+1.39%profit
Cipla

C

Cipla

1,384.00-0.07%loss
View Allarrow

NSE Indices Today

Index NamePrice
View Allarrow

Top Gainers Today

Stock NamePrice
View Allarrow

Top Losers Today

Stock NamePrice
View Allarrow

Open IPOs

View All IPOsarrow

Calculators

Brokerage Calculator

Brokerage Calculator

Margin Calculator

Margin Calculator

MTF Calculator

MTF Calculator

Stock Return Calculator

Stock Return Calculator

Stock Average Calculator

Stock Average Calculator

View Allarrow

What's New In The Market

View Allarrow

FAQs on NATCOPHARM

Natco Pharma share price as of today is ₹ 834.60 as on 07 Sep 2026 at 11:13 AM.
The 52W high of Natco Pharma is ₹ 1,226.80 and 52W low is ₹ 789.00 as of 07 Sep 2026 at 11:13.
The past returns of Natco Pharma share are -
  • Past 1 year: -2.45%
  • Past 3 years: -7.47%
  • Past 5 years: -16.08%
The PE and PB ratio of Natco Pharma stands at 13.00 and 1.61 respectively as on 07 Sep 2026 at 11:13.
The EPS of Natco Pharma is 11.53 for the quarter ended Jun 2026 and 79.20 for the financial year 2025-26.
The shareholding pattern of Natco Pharma is as follows:
  • DIIs - 5.62%
  • FII - 16.99%
  • Promoters - 49.42%
  • Public Investors 23.41%
  • Goverenment - 0.00%
Yes, you can buy shares of Natco Pharma online by opening Demat account with Dhan.
If you are a Dhan user already, you can buy Natco Pharma stocks from Dhan Trading App or Web Trading Platform. If you are new to Dhan follow the below steps:
  1. Download the Dhan App to Open a Demat Account
  2. Navigate to the “Money Tab”
  3. Add money to your account
  4. Search for Natco Pharma share
  5. Tap on “Buy”
With Dhan you can start a daily, weekly or monthly SIP in Natco Pharma.
You can easily buy the shares of Natco Pharma even after the markets are closed using the After Market Order feature on Dhan Trading App.


Invest & Trade with a Trading
Platform That's icon

Open your Dhan Account in minutes!


border
logo

Join our Community

community logo

Follow us on

twitter
telegram
Linkedin
youtube
instagram
facebook

built with love
for Indians who love to invest & trade

raise

We are part of Raise Financial Services

raise
raise

Explore  |  Sitemap


*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

We are doing so by giving you access to not just one but 6 products within the Dhan ecosystem:


This means that with Dhan, you'll be able to start:


Lakhs of users already trust Dhan for their online stock trading and investing needs. Dhan is growing rapidly because of the love we receive from SuperTraders and Long-Term Investors who acknowledge that the platform is innovating for them, building super useful features that help them do everything from investing in stock market to trading F&O like a pro on the Tradingview charts and much more.

While we are growing, we will always remember why we started building in the first place - you. Our user-first approach will always be at the heart of our philosophy. Come join us on this incredible journey!

Try it out, you can close your account at anytime using this link.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.

Details of client bank account

For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES/SMART ODR Portal: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com store apps sebiscores iOS: https://apps.apple.com app sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details | MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors | Master Circular for Online Dispute Resolution